Telepathic Technology: The Journey so far

Telepathic Technology: The Journey so far
The V1 Edition

Facebook, Musk, Kernel and even the US Government have recently been reported to have joined the race in telepathic technology. Their objectives range from tweeting 100 words a minute directly from the brain, to enhancing human intelligence by plugging people directly into the Internet. And while these ideas might seem like they came from the imaginings of a science-fiction writer, history shows us that they might not be so far-fetched.

It’s difficult to succinctly map out a history of Brain-Computer Interfacing (BCI). You could go all the way back to 1875, when British physician, Richard Caton, discovered electrical signals in animal brains, or to 1925, when German psychiatrist, Hans Berger, became the first person to record human brain activity. Likewise, from the late '60s through to 2000, intriguing developments were being made, often with rhesus monkeys. But, from the turn of the century onward, research moved into two areas that are of particular interest: non-invasive and commercial.    

In fact, scientists have had surprising success with invasive BCI. In 2000, MIT experiments showed monkeys controlling a robotic arm 600 miles away using brain signals. And, in 2005, tetraplegic Matt Nagle became the first human to control an artificial hand as part a nine month trial of Cyberkinetics’s BrainGate chip-implant.

But the next step is a non-invasive approach that can be used by the masses. As Mary Jepson, one of the industry’s biggest visionaries, said, “for this to really happen, it has to be noninvasive and it has to be removable.” The aim here is both medical and commercial.

The commercial use of BCI is nothing new. In 2007, NeuroSky – manufacturer of commercial BCI products – released a game where the user interacts with the controls via a headset, and, as of 2013, there’s even an annual “neurogaming” conference. However, the phenomenon is yet to take the world by storm.   

Bridging the gap between obscure and profitable will surely be one of the main aims from this latest surge in research. The question is, how feasible are the lofty ambitions being put forth?